Trial Profile
PERtuzumab-trastuzumab plus lEetrozoLe In endocrine Sensitive breast cancer: a phase II neoAdjuvant study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Oct 2022
Price :
$35
*
At a glance
- Drugs Letrozole (Primary) ; Pertuzumab (Primary) ; Trastuzumab (Primary) ; Paclitaxel
- Indications Early breast cancer; HER2 positive breast cancer
- Focus Therapeutic Use
- Acronyms PER-ELISA
- 13 Sep 2022 Results of A correlative analysis from the PerELISA trial evaluating the ability of HER2DX to predict efficacy of a de-escalated, chemotherapy free neoadjuvant regimen in HER2+HR+ breast cancer presented at the 47th European Society for Medical Oncology Congress
- 11 Sep 2022 Results published in the REVEAL GENOMICS Media Release.
- 11 Sep 2022 According to a REVEAL GENOMICS media release, data from the study was presented by Prof. Valentina Guarneri at the European Society of Medical Oncology Congress 2022.